bioMérieux S.A. (BMXXY) Comparison with companies in other sectors?

bioMérieux S.A. has a share price of 1.18B. You can analyze bioMérieux S.A. (BMXXY) competitors across different market sectors through stock heatmaps.

What are BMXXY's NET and operating margins?

bioMérieux S.A. (BMXXY) operating margin is around 0.14, and net profit margin is approximately 0.11 as of the latest reports.

In what way does BMXXY's earnings per share (EPS) trend reflect its financial momentum?

bioMérieux S.A. (BMXXY) EPS is 0.42 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for bioMérieux S.A. is 32.93, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for bioMérieux S.A.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for bioMérieux S.A. like P/E which is 33.85, P/B which is 3.31, and PEG which is 2.66. Compare them with sector averages to evaluate if the stock is priced fairly.

bioMérieux S.A.

BMXXY•PNK

Healthcare

Medical - Specialties

$13.83

$0.00(0.00%)

Fundamental Analysis of bioMérieux S.A. (BMXXY)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$0.42

P/E Ratio

32.93

ROE

0.10%

Net Margin

0.11%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$16.31B

Shares OutstandingTotal number of shares issued

$1.18B

Book Value/ShareNet worth per share

$35.60

Revenue/ShareAnnual revenue per share

$32.18

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.42

Net MarginNet income as percentage of revenue

10.81%

Operating MarginOperating income as percentage of revenue

13.65%

ROEReturn on shareholders' equity

10.19%

ROAReturn on total assets

7.13%

ROCEReturn on capital employed

11.21%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$1.32

Cash/ShareCash and equivalents per share

$3.80

FCF YieldFree cash flow as percentage of market cap

1.13%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$0.08

Dividend YieldAnnual dividend as percentage of stock price

0.71%

Financial Ratios Analysis data is not available for BMXXYFinancial Ratios Analysis details for BMXXY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for BMXXYSector Benchmarking details for BMXXY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for bioMérieux S.A. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of bioMérieux S.A.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account bioMérieux S.A.'s unique business strengths and challenges.

Key Financial Metrics for bioMérieux S.A.

For bioMérieux S.A., essential financial indicators include EPS 0.42, PE 32.93, and ROE 0.10. These key ratios reveal insights into bioMérieux S.A.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare bioMérieux S.A. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of bioMérieux S.A.

Metrics like Net Margin 10.81% and ROA 7.13% shed light on how well bioMérieux S.A. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether bioMérieux S.A. can sustain its operations and continue growing in the future.

Valuation and Market Position of bioMérieux S.A.

Using ratios such as P/B Ratio 3.31 and PEG Ratio 2.66, investors can assess whether bioMérieux S.A. is appropriately valued based on its financials and growth potential. These figures, combined with bioMérieux S.A.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for bioMérieux S.A.

Financial health indicators, such as Debt/Equity Ratio 0.12 and Cash Flow $1.32, provide a snapshot of bioMérieux S.A.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like bioMérieux S.A., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for bioMérieux S.A.

Investing in bioMérieux S.A. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at bioMérieux S.A. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;